Evaluation ofin vitro release profiles of fentanyl-loaded PLGA oligomer microspheres

被引:0
作者
Gilson Khang
Sun-Ah Seo
Hak Soo Choi
John M. Rhee
Hai Bang Lee
机构
[1] Chonbuk National University,Department of Polymer Science and Technology
[2] Korea Research Institute of Chemical Technology,Biomaterials Laboratory
来源
Macromolecular Research | 2002年 / 10卷
关键词
fentanyl; poly(; -lactide-; -glycolide); microspheres; solvent-evaporation method;
D O I
暂无
中图分类号
学科分类号
摘要
In order to the development of the delivery device of long-acting local anesthetics for postoperative analgesia and control of chronic pain of cancer patient, fentanyl-loaded poly(l-lactide-co-glycolide)|(PLGA, molecular weight, 5,000 g/mole; 50∶50 mole ratio by lactide to glycolide)|microspheres (FMS)|were studied. FMS were prepared by an emulsion solvent-evaporation method. The influence of several preparation parameters such as initial drug loading, PLGA concentration, emulsifier concentration, oil phase volume, and fabrication temperature has been investigated on the fentanyl release profiles. Generally, the drug showed the biphasic release patterns, with an initial diffusion followed by a lag period before the onset of the degradation phase, but there was no lag time in our system. Fentanyl was slowly released from FMS over 10 daysin vitro with a quasi-zero order property. The release rate increased with increasing drug loading as well as decreasing polymer concentration with relatively small initial burst effect. From the results, FMS may be a good formulation to deliver the anesthetic for the treatment of chronic pain.
引用
收藏
页码:246 / 252
页数:6
相关论文
共 136 条
  • [1] Hammargren W. R.(1988)undefined J. Anal. Toxicol. 12 183-183
  • [2] Henderson G. L.(1984)undefined J. Anal. Toxicol. 8 288-288
  • [3] Garriott J. C.(1987)undefined J. Anal. Toxicol. 11 272-272
  • [4] Rodriquez R.(1988)undefined J. Anal. Toxicol. 12 236-236
  • [5] Di Mario V. J. M.(1990)undefined Forensic Sci. Int. 45 247-247
  • [6] Pare E. M.(2001)undefined J. Chromatography B. 765 63-63
  • [7] Monforte J. R.(2002)undefined Int. J. Pharm. 234 195-195
  • [8] Gaul R.(2002)undefined Int. J. Pharm. 239 93-93
  • [9] Mirchandani H.(1985)undefined Adv. Contracept. 1 19-19
  • [10] Matecjczyk R. J.(1990)undefined J. Med. 152 617-617